HDAC1 and HDAC2 Control the Specification of Neural Crest Cells into Peripheral Glia

Claire Jacob,1,4* Pirmin Lütscher,1,4 Stefanie Engler,1,4 Arianna Baggiolini,1 Sandra Varum Tavares,3 Valérie Brügger,4 Nessy John,2 Stine Büchmann-Möller,2 Paige L. Snider,5 Simon J. Conway,5 Tepppei Yamaguchi,2 Patrick Matthias,2 Lukas Sommer,2 Ned Mantei,1 and Ueli Suter1

1Institute of Molecular Health Sciences, Department of Biology, ETH Zurich, CH-8093 Zurich, Switzerland, 2FMI for Biomedical Research, Novartis Research Foundation, CH-4058 Basel, Switzerland, 3Institute of Anatomy, University of Zurich, CH-8057 Zurich, Switzerland, 4Institute of Zoology, Department of Biology, University of Fribourg, CH-1700 Fribourg, Switzerland, and 5Developmental Biology and Neonatal Medicine Program, H.B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana 46202

Schwann cells, the myelinating glia of the peripheral nervous system (PNS), originate from multipotent neural crest cells that also give rise to other cells, including neurons, melanocytes, chondrocytes, and smooth muscle cells. The transcription factor Sox10 is required for peripheral glia specification. However, all neural crest cells express Sox10 and the mechanisms directing neural crest cells into a specific lineage are poorly understood. We show here that histone deacetylases 1 and 2 (HDAC1/2) are essential for the specification of neural crest cells into Schwann cell precursors and satellite glia, which express the early determinants of their lineage myelin protein zero (P0) and/or fatty acid binding protein 7 (Fabp7). In neural crest cells, HDAC1/2 induced expression of the transcription factor Pax3 by binding and activating the Pax3 promoter. In turn, Pax3 was required to maintain high Sox10 levels and to trigger expression of Fabp7. In addition, HDAC1/2 were bound to the P0 promoter and activated P0 transcription. Consistently, in vivo genetic deletion of HDAC1/2 in mouse neural crest cells led to strongly decreased Sox10 expression, no detectable Pax3, virtually no satellite glia, and no Schwann cell precursors in dorsal root ganglia and peripheral nerves. Similarly, in vivo ablation of Pax3 in the mouse neural crest resulted in strongly reduced expression of Sox10 and Fabp7. Therefore, by controlling the expression of Pax3 and the concerted action of Pax3 and Sox10 on their target genes, HDAC1/2 direct the specification of neural crest cells into peripheral glia.

Key words: histone deacetylases; neural crest cells; peripheral glia specification; transcriptional control

Introduction

Specification of neural crest cells into the Schwann cell lineage is instructed by neuregulin 1 (Shah et al., 1994) and requires the transcription factor Sox10, which induces the expression of the neuregulin receptor ErbB3 (Britsch et al., 2001; Prasad et al., 2011) and of the early determinants of Schwann cell precursors fatty acid binding protein 7 (Fabp7) and myelin protein zero (P0) (Kurtz et al., 1994; Hagedorn et al., 1999; Jessen and Mirsky, 2005). Sox10 is expressed in neural crest cells and remains expressed in peripheral glia, whereas it is downregulated in other neural crest-derived cells (Kuhlbrodt et al., 1998). Pax3 is another key transcription factor for neural crest cells and several of their derived lineages (Auerbach, 1954). In the absence of Pax3, dorsal root ganglia (DRG) are smaller (Auerbach, 1954; Olaopa et al., 2011) and Schwann cells are strongly reduced in number or absent (Franz, 1990). In the mouse Schwann cell lineage, Pax3 is expressed until embryonic day 13.5 (E13.5) and is then turned off and reexpressed at later stages, where it participates in the control of the Schwann cell cycle (Kioussi et al., 1995; Doddrell et al., 2012).

Although Sox10 is clearly critical for peripheral glia specification, the mechanisms controlling Sox10 expression and activity in neural crest cells during this process remain unclear. As for Pax3, canonical Wnt signaling has been shown to activate the Pax3 promoter through Cdx transcription factors in Neuro2a cells (Sanchez-Ferras et al., 2012) to induce sensory neurogenesis and melanocyte formation, but not specification of peripheral glia (Hari et al., 2012). Therefore, the mechanisms regulating Pax3 expression in neural crest cells and Pax3-dependent control of peripheral glia specification are not known.

We investigated the potential involvement of histone deacetylases (HDACs) in this process. HDACs are transcriptional regulators that deacetylate histones to modify chromatin architecture (de Ruijter et al., 2003; Michan et al., 2007) or deacetylate tran-
scription factors to modulate their activity (Glozak et al., 2005; Yao et al., 2011). Histone deacetylation was long thought to only result in gene silencing by local compaction of the chromatin structure. However, HDACs are also needed to keep genes in an active state (Wang et al., 2009) by acting in concert with histone acetyltransferases (HATs). Therefore, the level of histone acetylation and the presence of HDACs at a gene locus do not always reflect the activity status of a gene. Here, we elucidate HDAC functions in conjunction with their binding partners that allow recruitment to their critical target genes to modulate transcriptional activity. We demonstrate that the highly homologous HDAC1 and HDAC2 are essential for the specification of neural crest cells into Schwann cell precursors and satellite glia. HDAC1/2 induced Pax3 expression in neural crest cells. In turn, Pax3 maintained high Sox10 levels during specification. HDAC1/2 also activated P0 expression in neural crest cells. These mechanisms were necessary for expression of early determinants of Schwann cells and satellite glia and therefore for their specification.

**Materials and Methods**

*Plasmids.* Sox10 shRNA-1 (MISSION shRNA clone reference #TRCN0000239154; Sigma) and Sox10 shRNA-2 (MISSION shRNA clone reference #TRCN0000242490; Sigma), Mouse Sox10 MCSIC (plasmid 20240, Addgene; Antonelli et al., 2008), mouse Sox10 MCSI (kind gift from A. McCallion, Johns Hopkins University School of Medicine, Baltimore, MD), human Fabp7 promoter (kind gift from G. Marfany, Universitat de Barcelona, Barcelona, Spain), rat P0 promoter (kind gift from G. Lemke, The Salk Institute, La Jolla, CA), mouse Pax3 promoter (kind gift from I. Sernjace, University of Ottawa, Ontario, Canada), pbJS-HDAC1-overexpression construct (kind gift from S. Schreiber, Broad Institute, Cambridge, MA), pME1 S HDAC2-overexpression construct (kind gift from E. Seto, Lee Moffitt Cancer Center and Research Institute, Tampa, FL), Sox10-overexpression construct (kind gift from M. Wegner, Universitat Erlangen-Nürnberg, Erlangen, Germany), and Pax3 overexpression construct (Addgene plasmid 27319, Epstein et al., 1995). Constructs for *in situ* hybridization were as follows: Hdac1 (EST clone, IMAGE ID: 4976514), Hdac2 (mouse full-length cDNA was cloned into the pCMV-Sport6 expression vector), Pax3 (kind gift from M. D. Goulding, The Salk Institute for Biological Studies, La Jolla, CA), Po (kind gift from G. Lemke, The Salk Institute, La Jolla, CA and R. Axel, Columbia University, New York, NY), and Fabp7 (EST clone, IMAGE ID: 5700428).

*Generation of lentiviruses and transduction of JoMa1 cells.* We previously described HDAC1 shRNA and control shRNA lentiviral constructs (Jacob et al., 2011). We designed a mouse HDAC2-specific shRNA and a Pax3-specific shRNA using Dharmacon siDESIGN Center and 2-shRNA Oligo Designer (http://www.unc.edu/~call/biotool/2shRNA.html). Targeting sequences were as follows: H2sh2, GACGGTCCTCATTCAAA; Pax3sh2, GGAAGGAAGAGACAAGAGAG. We cloned the corresponding shRNA oligonucleotides (synthesized by Microsynth) into pLentiLox 3.7 lentiviral plasmid (ATCC) using either HpaI/XhoI or BglII/EcoRI. Lentiviruses were produced using pSiCoR-GFP-EF1α (Addgene plasmid 27319, Alex Fluor 488 (1:500; Invitrogen, RRID:AB_141607), goat polyclonal; DCS, RRID:AB_2313583), Pax3 (1:100, mouse monoclonal; Santa Cruz Biotechnology, RRID:AB_219573), cleaved Caspase 3 (1:500, 9661, rabbit polyclonal; Cell Signalling Technology), Sox10 (1:200, N-20, sc-17342, goat polyclonal; Santa Cruz Biotechnology, RRID:AB_2195734) or 1:200, SI058C01, rabbit polyclonal; DCS, RRID:AB_2313583), Pax3 (1:100, mouse monoclonal; Developmental Studies Hybridoma Bank, RRID:AB_528426), NeuroD1 (1:200, sc-1084, goat polyclonal; Santa Cruz Biotechnology, RRID:AB_630922), and Islet1 (1:200, 39.4D5, mouse monoclonal; Developmental Studies Hybridoma Bank, RRID:AB_528426). The secondary antibodies used were as follows: donkey anti-mouse Alexa Fluor 488 (1:500; Invitrogen, RRID:AB_141607), donkey anti-
rabbit Cy5 (1:200; Jackson ImmunoResearch, RRID:AB_2307444), donkey anti-rabbit Alexa Fluor 488 (1:500; Jackson ImmunoResearch, RRID:AB_2313584), and donkey anti-goat Cy3 (1:500; Jackson ImmunoResearch, RRID:AB_2307351).

Cells or sections were observed using a fluorescence microscope (Axioplan2 Imaging; Carl Zeiss) with 20×/0.50 numerical aperture (NA), 40×/0.75 NA, or 63×/1.25 NA (oil-immersion) plan Neofluar objectives. Images were digitized with a PowerShot G5 camera (Canon) and acquired with AxioVision 4.5 software (Carl Zeiss). For confocal analyses, cells were observed using a Leica DMIRE2 inverse microscope and a Leica SP2 AOBS point laser scanning confocal. Optical sections were collected at 2.0 μm intervals using Leica LCS software. Images were assembled and the brightness and contrast were adjusted using Adobe Photoshop CS5 12.0.4. Where indicated in the figure legends, z-series projections were generated using ImageJ 1.46r software (RRID:nif-0000-30467). Quantification analyses were done with CellProfiler 2.0 software (Broad Institute, RRID:nif-0000-00280).

In situ hybridization with digoxigenin-labeled riboprobes was performed on cryosections as described previously (Paratore et al., 1999). Hybridization signals were visualized with NBT/BCIP (Roche Diagnostics). Antisense riboprobes were labeled with digoxigenin according to the manufacturer’s instructions (Roche Diagnostics).

Western blot and immunoprecipitation. Twenty-four hour differentiated for immunoprecipitations, IPs, or 4 d differentiated (for Western blot) or undifferentiated conditions. For HDAC1/2 inhibition, cells were first incubated with 0.6 μM Mocetinostat (Selleckchem) for 48 h in undifferentiated conditions before transfection and induction of differentiation. Luciferase activity was first normalized to a luciferase-empty control (transfected with the overexpressing construct at the same ratio of Fugene 6:DNA), and then normalized to β-galactosidase activity (assay according to the instructions of Promega). Results are expressed as percentage of the control.

For transfection, Fugene 6 (Roche) was used at a 3:1 ratio of Fugene 6:DNA, according to the manufacturer’s recommendations with the following modification: the DNA was incubated in OptiMEM for 5 min at room temperature before addition of Fugene 6. The mix Fugene 6:DNA was then incubated for 25 min at room temperature before being added to cells. Cells were lysed in 110 μl of reporter lysis buffer (Promega) and assayed for luciferase activity. Forty microliters of lysate were subjected to two consecutive injections of 25 μl of luciferase substrate and values were recorded after an integration time of 30 s. Efficiency of transfection was evaluated by measuring β-galactosidase activity of a cotransfected lacZ construct (Promega). Beta-galactosidase activity assay was as follows: 50 μl of assay buffer was added to 50 μl of lysate and β-galactosidase activity was recorded after a 15–20 min incubation time at 37°C. Endogenous β-galactosidase activity (as determined from cells transfected only with overexpressing or shRNA constructs at the same ratio of Fugene 6:DNA) was subtracted.

We have verified that no significant change of luciferase activity of the empty luciferase construct pGL3 (backbone construct; Promega) occurred when overexpressing or shRNA constructs were transfected. Cells were cotransfected with 0.8 μg of luciferase construct (Sox10 MCS4, Sox10 MCS1C, P0 promoter, Pax3 promoter, Fabp7 promoter); 0.8 μg of GFP-βgalactosidase construct, or HDAC2-overexpressing construct; between 0.05 and 0.8 μg of Sox10- or Pax3-overexpressing construct, 0.8 μg of shRNA construct (control shRNA; HDAC1 shRNA, HDAC2 shRNA, Pax3 shRNA, Sox10 shRNAs), and 300 ng of lacZ construct.
Figure 2. HDAC1/2 activity is required to maintain high Sox10 levels and for Sox10-dependent activation of Sox10, Fabp7 and P0 gene regulatory regions during specification into glia. A, Immunofluorescence of Sox10 (red; DAPI = nuclei in blue) on mouse neural crest explants in differentiating conditions with or without the HDAC1/2 inhibitor mocetinostat (HDAC1/2i; 0.6 μM), and quantification of Sox10 (200 cells per explant, 3 explants per condition, n = 3). Relative luciferase activity of Sox10 MCS4 (B, C), Sox10 MCS1C (= Sox10 promoter region, B), Fabp7 promoter (D), and P0 promoter (E) driven luciferase reporter constructs (-luc) induced by Sox10 overexpression compared with GFP (= 1) with or without HDAC1/2i (C–E) 24 h after transfection and induction of differentiation in postnatal primary rat Schwann cells (B) or in JoMa1 cells (B–E). p-values from two-tailed unpaired (A) or paired (B–E) Student’s t-test: 0.0063 (A); *0.0193, ***6.91462E-06 (B); **0.0029, ***0.0001, + +0.026 (C); ***0.0001, +0.017 (D); and **0.0041, + + +0.028 (E). Results are from at least three independent experiments. Error bars indicate SEM.

Quantitative real-time PCR. Isolation of RNA was performed using TRIzol reagent (Invitrogen) according to the manufacturer’s recommendations. cDNA was produced using SuperScript III Reverse Transcriptase (Invitrogen). Quantitative real-time PCR (qRT–PCR) analyses were performed on an ABI 7000 Sequence Detection System (Applied Biosystems) using 2X SYBR Green PCR Mastermix (Applied Biosystems) according to the manufacturer’s recommendations.

Primary sequences were as follows: for P0, forward 5’-CCCTGGCCAT-TGTGTTTAC-3’; reverse 5’-CCATTCACTGGACCAGAAGG-3’; for GAPDH, forward 5’-GTACGGGTACTTACAACAAATGGC-3’; reverse 5’-TTGGCATCTGGTGATTCG-3’. The amplification program was as follows: 5 min at 96°C; 40 steps of 30 s at 96°C, 30 s at 60°C, 30 s at 72°C, and 5 min at 72°C.

ChIP. Experiments with JoMa1 neural crest cells were performed as described previously (Jacob et al., 2011). Two micrograms of antibodies were used per IP.

The antibodies used were as follows: mouse anti-HDAC2 (H2663; Sigma Aldrich), rabbit anti-HDAC1 (PA1–860; Affinity BioReagents), goat anti-Sox10 (N-20, sc-17342; Santa Cruz Biotechnology), mouse anti-Pax3 (Developmental Studies Hybridoma Bank), mouse anti-HH3 (positive control; Millipore, RRID:AB_309763), or rabbit anti-mouse IgG (negative control; Sigma, RRID:AB_260634).

Results
HDAC1 and HDAC2 are robustly expressed during specification of neural crest cells into peripheral glia

We found that HDAC1 and HDAC2 were widely expressed in the neural tube and surrounding tissue at E10.5 in developing mouse embryos (Fig. 1A). At E11.5, however, HDAC1/2 expression was concentrated in the neural tube and in DRG (Fig. 1A) and remained highly expressed in these structures and in peripheral nerves at E12.5 and E14.5 (data not shown). Specification of neural crest cells into peripheral glia occurs at E11 (Jessen and Mirsky, 2005). Because HDAC1/2 expression was maintained during this process in DRG, we investigated the potential involvement of HDAC1/2 in the transcriptional control of peripheral glia specification. We initially used the neural crest cell-derived line JoMa1, which differentiates into glia upon treatment with the neuroregulin 1 isoform heregulin-beta1 (Maurer et al., 2007). Within 4 d, heregulin-beta1 upregulated Sox10 (Fig. 1B) and the early glial marker Fabp7 (Fig. 1C) and led to a mild but significant upregulation of HDAC1 (Fig. 1D) and HDAC2 (Fig. 1E) in these cells.
Interestingly, a second HDAC2 band of slightly higher molecular weight appeared in glia-differentiated JoMa1 cells, indicating posttranslational modification of HDAC2 during this process. Together, these data confirmed that the JoMa1 neural crest cell line can be specified into glia upon heregulin-beta1 treatment and was therefore suitable for our study. In addition, the robust expression of HDAC1/2 concomitant with Sox10 upregulation prompted us to seek a potential involvement of HDAC1/2 in the regulation of peripheral glia specification.

HDAC1/2 activity is required to maintain high Sox10 expression and for Sox10-dependent activation of Sox10, Fabp7, and P0 gene regulatory regions during specification into glia

Precise regulation of Sox10 expression is critical for specification of neural crest cells into glia (Paratore et al., 2001). To determine whether HDAC1/2 activity is involved in the control of Sox10 expression during this process, we chose to use mouse neural crest explants because the myc-immortalized JoMa1 cell line may not completely mirror all transcriptional regulations that occur in normal neural crest. We induced glia specification in mouse neural crest explants in the presence of the HDAC1/2-specific inhibitor mocetinostat (0.6 μM) and analyzed Sox10 levels. At this concentration, mocetinostat is a specific inhibitor of HDAC1/2 (IC50 for HDAC1 0.15 μM, IC50 for HDAC2 = 0.29 μM). It also becomes active on HDAC3 at higher concentrations (IC50 for HDAC3 = 1.66 μM). Inhibition of HDAC1/2 activity strongly decreased Sox10 expression (Fig. 2A) without a significant increase in cell death (data not shown), indicating that HDAC1 and/or HDAC2 is necessary to maintain high Sox10 expression during specification of neural crest cells into glia.

To determine the underlying molecular mechanism, we started from the fact that Sox10 upregulates its expression by binding and activating its own promoter and 5’ enhancers (Werner et al., 2007; Antonellis et al., 2008). Activation of the Sox10
HDAC2 controls Pax3 expression in neural crest cells. A, Western blot of Pax3 and quantification normalized to GAPDH in 4 d differentiated (Diff.) compared with undifferentiated (Undiff.) JoMa1 cells. B, Immunofluorescence of Pax3 (green; DAPI = nuclei in blue) in neural crest explants in differentiating conditions with or without the HDAC1/2 inhibitor mocetinostat (HDAC1/2i, 0.6 μM) and quantification of Pax3 (~200 cells per explant, 3 explants per condition, n = 3). Relative lucerase activity of Pax3 promoter-luc upon HDAC1 (H1), HDAC2 (H2) or Sox10 overexpression (C) with or without Sox10 shRNAs (510sh) or in the presence of Sox10 shRNAs alone (F) compared with GFP (= 1) or GFP/control shRNA (GFP/Csh = 1) 24 or 72 h (shRNA) after transfection and 24 h of induction of differentiation or in the presence of H1 shRNA (sh) or H2sh compared with Csh (= 1) (D) 72 h after transfection and 24 h in differentiating conditions. E, Western blot of HDAC2, Pax3, and GAPDH in JoMa1 cells expressing endogenous HDAC2 (C, control) or overexpressing HDAC2 (H2o). A lentiviral vector was used to overexpress HDAC2. Control cells were transfected with a lentiviral vector expressing GFP. Cells were collected 72 h after transduction and induction of differentiation. Dividing lines indicate that samples have been loaded on the same gel, but not on consecutive lanes. G, ChIP showing relative binding of anti-HDAC1 (H1) and anti-HDAC2 (H2) antibodies to Pax3 promoter (Pax3 pro) or control sequence (control seq.) compared with negative control (IgG = neg = 1). H, ChIP showing relative binding of anti-Sox10 antibody to Sox10/MCS4, Sox10/MCS1C, Pax3 promoter (pro), Fabp7 pro, or control sequence region (control seq.) compared with negative control (IgG = neg = 1), 24 h after induction of differentiation. p-values compared with control (H1/Csh) or unpaired in B unless stated otherwise: 0.044 (A); 0.164 (B); *0.041, **0.0016 (C); 0.003 (D); 0.04 (E); *0.047, 0.031, 0.048, *0.0032, **0.0016, ***0.0002 (F, p-values compared with control GFP/Csh), +0.026, 0.04, 0.028, 0.027 (F, p-values compared with H1/Csh for H1/510sh or to H2/Csh for H2/510sh); *0.027 and **0.0019 (G); 0.033 (one-tailed) and 0.0125 (two-tailed; H). Results are from at least three independent experiments. Error bars indicate SEM.

MCS4 enhancer (also called U3) by Sox10 is critical for Sox10 expression in neural crest cells (Wahlbuhl et al., 2012). First, we used the luciferase gene reporter assay to test the activity of the Sox10 MCS4 enhancer and of Sox10 MCS1C (Sox10 promoter) in JoMa1 cells and postnatal primary Schwann cells upon Sox10 overexpression (Fig. 2B,C). Sox10 MCS4 was strongly activated in JoMa1 cells, whereas Sox10 MCS1C was not. In contrast, Sox10 MCS4 was not activated in postnatal Schwann cells, whereas Sox10 MCS1C was (Fig. 2B). These findings confirm the findings of Werner et al. (2007) and extend the importance of these two regulatory regions at different stages of development. Sox10 overexpression also robustly activated the promoters of the early determinants of Schwann cells, Fabp7 (Fig. 2D) and P0 (Fig. 2E), in JoMa1 cells.

Exogenous DNA transiently applied in cells is present in nucleosomal DNA at approximately the same levels as endogenous DNA (Zhang et al., 2002). We therefore tested the effects of HDAC1/2 inhibition in these validated settings. Inhibition of HDAC1/2 activity decreased Sox10-induced activation of Sox10 MCS4 (Fig. 2C), the Fabp7 promoter (Fig. 2D), and the P0 promoter (Fig. 2E). Therefore, HDAC1 and/or HDAC2 are needed for Sox10-dependent activation of these regulatory elements.

P0 is a direct target gene of HDAC2, whereas HDAC2-dependent activation of Sox10 MCS4 and the Fabp7 promoter is most likely indirect.

In JoMa1 cells cultured in differentiating conditions, overexpression of HDAC2 and, to a lesser extent, of HDAC1 increased the activation of the P0 promoter, as detected by luciferase gene reporter assay 24 h after transfection (Fig. 3A), and increased the transcript levels of P0 48 h after transfection (Fig. 3B). To bind DNA, HDACs need to interact with a DNA-binding protein. Because Sox10 binds and activates the Sox10 P0 promoter (Peirano and Wegner, 2000; Peirano et al., 2000; Fig. 2E) and increases P0 transcript levels (Fig. 3B), we tested whether HDAC1/2-induced activation of the P0 promoter requires Sox10 by downregulating Sox10 with specific shRNAs (Fig. 3C). Indeed, this activation was suppressed when Sox10 was downregulated (Fig. 3D), indicating that HDAC1/2-mediated activation of the P0 promoter is Sox10 dependent.

HDAC2 activated Sox10 MCS4 and the Fabp7 promoter 60 h after transfection (Fig. 3E,F), but not after 24 h, suggesting an indirect activation mechanism. In contrast, the P0 promoter is likely to be activated in a direct manner. Indeed, using ChIP, we found HDAC2 bound to the P0 promoter 24 h after induction of
differentiation in JoMa1 cells (Fig. 3G). We previously showed that HDAC1/2 interact with Sox10 upon induction of differentiation in postnatal Schwann cells to activate the Sox10 promoter and the Krox20 myelinating Schwann cell element (Krox20 MSE; Jacob et al., 2011). In JoMa1 cells also, Sox10 coimmunoprecipitated with HDAC2 and this interaction was significantly increased 24 h after induction of specification into peripheral glia (Fig. 3F). Together, these data indicate that HDAC2 interaction with Sox10 in neural crest cells increases upon induction of specification into glia to bind and activate the P0 promoter.

**Pax3 is a direct target gene of HDAC2 in neural crest cells**

To understand how HDAC2 controls the differentiation in neural crest cells. Pax3 is necessary for HDAC2-dependent activation of **Pax3**

Overexpression of HDAC2 or Sox10 in JoMa1 cells rapidly (24 h after transfection) activated the **Pax3** promoter (Fig. 3C), whereas downregulation of HDAC2 by shRNA resulted in decreased activity (Fig. 3D). Consistently, HDAC2 overexpression resulted in increased Pax3 expression levels (Fig. 3E). Because HDAC2 interacted with Sox10 in JoMa1 cells (Fig. 3F) and both HDAC2 and Sox10 overexpression activated the **Pax3** promoter (Fig. 3G), we tested whether Sox10 is involved in HDAC2-mediated activation of the **Pax3** promoter. HDAC2-induced activation of the **Pax3** promoter was abolished when Sox10 was downregulated by shRNAs (Fig. 3F), showing that this activation is Sox10 dependent. Furthermore, we found that HDAC1 and HDAC2 were highly enriched at the **Pax3** promoter (Fig. 3G). Sox10 was also bound to the **Pax3** promoter, but not to Sox10 MCS1C or the **Fabp7** promoter (Fig. 3H). Consistent with previous studies (Werner et al., 2007; Antonellis et al., 2008; Wahlbuhl et al., 2012), Sox10 was bound to Sox10 MCS4 (Fig. 3H). These data strongly suggest that HDAC1/2 are recruited by Sox10 to the **Pax3** promoter. We conclude that Sox10 and HDAC2 control Pax3 expression in neural crest cells directly by binding and activating the **Pax3** promoter.

**Pax3 is necessary for HDAC2-dependent activation of Sox10 MCS4 and for expression of early determinants of peripheral glia during specification**

We next hypothesized that *Pax3* could be the critical HDAC2 intermediate target gene required for the maintenance of high Sox10 expression during specification of neural crest cells into glia. To test this hypothesis, we generated a lentiviral vector that carries a specific Pax3 shRNA to downregulate Pax3 in neural crest cells. Pax3 downregulation in JoMa1 cells resulted in significantly reduced Sox10 and Fabp7 expression (Fig. 5A), indicating that Pax3 is necessary for Sox10 and Fabp7 expression in neural crest cells.

Consistent with previous data (Wahlbuhl et al., 2012), mild Pax3 overexpression activated Sox10 MCS4 in JoMa1 cells, whereas high overexpression did not (Fig. 5B). In contrast, Sox10 MCS4 activation increased with the amount of overexpressed Sox10 (Fig. 5B). Pax3-binding sites on Sox10 MCS4 are adjacent to Sox10-binding sites (Wahlbuhl et al., 2012). Therefore, high levels of Pax3 may limit the access of Sox10 to its own binding sites and prevent Sox10-induced activation of Sox10 MCS4. In addition, Sox10 and Pax3 can interact (Lang and Epstein, 2003), so an excess of Pax3 could sequester Sox10 away from its target genes. Because low levels of Pax3 activated Sox10 MCS4 (Fig. 5B), residual Pax3 expression in the presence of shRNA is likely to be sufficient to maintain Sox10 at moderate levels (Fig. 5A).

Pax3 downregulation reduced Sox10 MCS4 activation and prevented HDAC2-induced Sox10 MCS4 activation (Fig. 5C). Pax3 also rapidly activated the P0 promoter 24 h after transfection and induction of differentiation (Fig. 5D), but not the **Fabp7** promoter (data not shown). Pax3 is known to bind Sox10 MCS4 (Wahlbuhl et al., 2012). We confirmed this binding in JoMa1 cells and found Pax3 to be additionally enriched at the P0 promoter, but not at the Sox10 MCS1C (Fig. 5E). These data indicate that Pax3 is required for HDAC2-dependent maintenance of high Sox10 levels and expression of peripheral glia proteins during specification of neural crest cells into glia.

**In vivo**, HDAC1/2 are essential in neural crest cells for Pax3 expression, maintenance of high Sox10 levels, and specification into peripheral glia

Next, we wanted to validate the relevance of HDAC1/2 functions in peripheral glia specification *in vivo*. Although HDAC1 and
HDAC2 can have distinct primary functions, they efficiently compensate for the loss of each other (Jacob et al., 2011). Therefore, we depleted both HDACs in neural crest cells. To this end, we crossed mice carrying floxed *Hdac1* and floxed *Hdac2* (Yamaguchi et al., 2010) and expressing the Cre recombinase under control of the *Wnt1* promoter (*Wnt1-Cre*; Danielian et al., 1998). Although no detectable decrease of HDAC1/2 protein levels was observed at E9.5, HDAC1/2 were efficiently ablated at E10 from DRG and peripheral nerves of double HDAC1/HDAC2 homozygous knock-out embryos (dKO, Fig. 6A). For *in vivo* fate mapping of neural crest cells, we included a Cre-dependent *LacZ* reporter allele on dKO and control embryos. Although smaller than in control embryos, DRG were formed in dKO embryos at E10.5 and E11.5, as well as peripheral nerves (Fig. 6B). These findings indicate that neural crest migration was not massively affected by the loss of HDAC1 and HDAC2. Consistent with our cell culture data, Sox10 protein levels were robustly decreased at E10.5 and E11 in dKO DRG compared with controls (Fig. 6C). Although the number of apoptotic cells in DRG was increased in dKO embryos at E10.5 and E11, Sox10-positive cells in control DRG (normal Sox10 levels) or in dKO DRG (low Sox10 levels) were rarely positive for cleaved Caspase 3 (Fig. 6D). We conclude that cells expressing Sox10 at detectable levels in dKO DRG did not undergo increased apoptosis. Pax3 was present in Sox10-expressing cells of control DRG, but absent in cells of dKO DRG (Fig. 6E). We confirmed this absence by *in situ* hybridization (Fig. 6F). Also consistent with our *in vitro* data, Fabp7 and P0 transcripts, expressed in DRG and/or peripheral nerves, were not detected in...
these structures in dKO embryos (Fig. 6F,G). Similar to dKO embryos, Sox10 and Fabp7 expressions were strongly reduced in Wnt1-Cre Pax3 knock-out DRG (Fig. 7A,B) and DRG were smaller (Olaopa et al., 2011 and data not shown).

**HDAC1/2 are not essential for overall sensory neurogenesis or for differentiation of cardiac neural crest cells**

To determine whether HDAC1/2 are also required for specification of neural crest cells into sensory neurons or cardiac neural crest, we used specific markers of neurons in DRG and of differentiated cardiac neural crest cells in the heart outflow tract of dKO and control embryos.

There are two waves of sensory neurogenesis, the first occurring at E9.5 and the second at E10 in mouse embryos (Ma et al., 1999). Newborn sensory neurons express the transient marker NeuroD1 and the pan-sensory neuronal marker Islet1. Therefore, at E10.5, sensory neurons generated during the first wave express Islet1, but do not express NeuroD1 anymore, whereas sensory neurons of the second wave are NeuroD1 and Islet1 positive. At E10 and E10.5, we detected both NeuroD1/Islet1-double positive cells and Islet1-positive/NeuroD1-negative cells in DRG of dKO embryos and controls (Fig. 8A). We cannot address whether HDAC1/2 are necessary for the first wave of sensory neurogenesis because onset of HDAC1/2 loss in dKO neural crest cells is at E10. However, we can state that specification of neural crest cells into sensory neurons of the second wave occurs in the absence of HDAC1/2. Nevertheless, the number of sensory neurons was reduced in dKO DRG compared with controls (data not shown). Islet1-positive cells were rarely positive for cleaved caspase 3 (cCasp3; Fig. 8B) in DRG of E10.5 dKO. Therefore, specified sensory neurons did not undergo massive apoptosis. Rather, the reduced number of sensory neurons may be explained by reduced proliferation of DRG sensory neurons in the absence of HDAC1/2 (data not shown).

In vivo fate mapping revealed that cardiac neural crest cells were also able to migrate to the branchial arches and the heart outflow tract and to differentiate in the absence of HDAC1/2, as shown by X-Gal staining and the expression of the differentiation markers Sox9 and smooth-muscle actin (SMA) in dKO and control embryos carrying also the Cre-dependent LacZ allele (Fig. 8C). However, the number of cardiac neural crest cells was reduced, possibly due to increased apoptosis, as detected by cCasp3 stainings in dKO branchial arches and heart outflow tracts compared with controls (Fig. 8C).

**Discussion**

Schwann cells, the myelinating cells of the PNS, are essential for the survival and the functions of peripheral neurons. In addition, Schwann cells are remarkably plastic, which enables them to foster axonal regeneration after a lesion. Because of their exceptional regenerative properties, Schwann cells are under consideration in transplantation paradigms when large lesions of the PNS have occurred and for regeneration of lesions in the CNS. To use these cells in regenerative medicine, it is critical to know how to control their cell cycle and to understand how they specify and differentiate, all the more so because stem cells are often used to generate Schwann cells for transplantation.

Specification of neural crest cells into Schwann cells and satellite glia requires the transcription factor Sox10 (Britsch et al., 2001). However, all neural crest cells express Sox10 and the mechanisms that drive neural crest cells into the peripheral glia lineage remain unclear. The aim of this study was to elucidate these mechanisms. By combining the use of the JoMa1 neural crest cell line, mouse neural crest explant cultures, and mouse genetics, we demonstrate that HDAC1/2 are essential transcriptional regulators of neural crest specification into Schwann cells and satellite glia.

HDACs are chromatin-remodeling enzymes that control DNA access for the transcriptional machinery by removing acetyl groups from histone tails. DNA is negatively charged and histones are positively charged. The addition of acetyl groups to histone tails neutralizes their positive charges. This leads to less interaction between DNA and histones, thereby resulting in a more relaxed chromatin that facilitates the access for transcription factors. In contrast, when acetyl groups are removed by HDACs from histone tails, histones recover their positive charges, which leads to a tightly wound DNA around histones that results in a more condensed chromatin. Because histone deacetylation favors chromatin compaction, HDACs are commonly seen as transcriptional repressors. However, the effect of HDACs on chromatin compaction is more complex. Indeed, many lysine residues of histones can be acetylated or deacetylated, allowing for different degrees of chromatin compaction. It is thus conceivable that, depending on the degree of chromatin compaction, HDACs can either block DNA access for the transcriptional machinery and thereby silence gene expression or only limit this access for selected transcription factors to induce expression of specific genes or activation of specific gene loci. Another mechanism by which HDACs control transcription at the chromatin level has been demonstrated in a study by Wang et al. (2009) showing that HATs and HDACs act in concert to maintain genes in a transcriptionally active state. Therefore, HDACs do not always repress transcription, but can also be necessary for transcriptional activity. Our previous work shows that HDAC1/2 bind to the Sox10 promoter and the
Figure 8. In the absence of HDAC1/2, sensory neurons are specified and cardiac neural crest cells express differentiation markers. A, Confocal pictures of NeuroD1 (red) and Islet1 (green) coimmunofluorescence in E10 and E10.5 control and HDAC1/2 dKO DRG. Overlay of NeuroD1 and Islet1 appears yellow. B, Confocal pictures of Islet1 (green) and cCasp3 (red) coimmunofluorescence and DAPI (blue) labeling in E10.5 control and HDAC1/2 dKO DRG. White arrows indicate cCasp3-positive DRG cells. C, In vivo cell fate mapping by X-Gal staining (black arrowheads) and SMA (green, open arrowheads), cCasp3 (red, white arrowheads) coimmunofluorescence, and DAPI (blue) labeling in E10.5 control and HDAC1/2 dKO heart outflow tract. The white arrow shows nonspecific auto-fluorescence signal. Scale bar, 100 μm. For each panel, representative photographs of three controls and three dKOs for each developmental stage are shown.
the Schwann cell lineage that may be responsible for the recruitment of these complexes to different gene regulatory regions. In summary, we demonstrate that HDAC1/2 are required for Pax3 expression in neural crest cells and that Pax3 is necessary for HDAC2-dependent control of Sox10 levels and expression of early determinants of Schwann cells and satellite glia. In addition, HDAC1/2 control the expression of P0 directly. By regulating the interplay between Sox10 and Pax3 and the expression of their target genes, HDAC1/2 are thus essential for specification of neural crest cells into peripheral glia.

References


